A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

As she prepares to change medications for her MS, columnist Leigh Anne Nelson explores the U.S. government’s registry on ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

Multiple Sclerosis Awareness Month highlights education, advocacy, research support, and ways to uplift the MS community throughout March.

Sanofi drug faces FDA delay following a failed late-stage trial for multiple sclerosis, with regulatory guidance expected by Q1 2024.

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.

New research reveals that when gut bacteria closely resemble the myelin sheath that protects nerve fibers, the immune system can become confused and attack both — accelerating multiple sclerosis.

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...

IU quarterback Fernando Mendoza, a Heisman Trophy finalist, gives back to families affected by Multiple Sclerosis, raising ...